ScinoPharm Taiwan Valuation
| 1789 Stock | TWD 22.20 0.50 2.20% |
At this time, the company appears to be fairly valued. ScinoPharm Taiwan has a current Real Value of NT$23.08 per share. The regular price of the company is NT$22.2. Our model measures the value of ScinoPharm Taiwan from inspecting the company fundamentals such as Return On Equity of 0.0295, operating margin of 0.12 %, and Shares Outstanding of 790.74 M as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that ScinoPharm Taiwan's price fluctuation is very steady at this time. Calculation of the real value of ScinoPharm Taiwan is based on 3 months time horizon. Increasing ScinoPharm Taiwan's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ScinoPharm stock is determined by what a typical buyer is willing to pay for full or partial control of ScinoPharm Taiwan. Since ScinoPharm Taiwan is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ScinoPharm Stock. However, ScinoPharm Taiwan's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.2 | Real 23.08 | Hype 22.2 |
The intrinsic value of ScinoPharm Taiwan's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ScinoPharm Taiwan's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ScinoPharm Taiwan helps investors to forecast how ScinoPharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ScinoPharm Taiwan more accurately as focusing exclusively on ScinoPharm Taiwan's fundamentals will not take into account other important factors: ScinoPharm Taiwan Total Value Analysis
ScinoPharm Taiwan is presently anticipated to have takeover price of 16.28 B with market capitalization of 20.44 B, debt of 2.29 B, and cash on hands of 4.72 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the ScinoPharm Taiwan fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
16.28 B | 20.44 B | 2.29 B | 4.72 B |
ScinoPharm Taiwan Investor Information
About 59.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.92. In the past many companies with similar price-to-book ratios have beat the market. ScinoPharm Taiwan last dividend was issued on the 7th of July 2022. The entity had 1040:1000 split on the 10th of August 2017. Based on the analysis of ScinoPharm Taiwan's profitability, liquidity, and operating efficiency, ScinoPharm Taiwan is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.ScinoPharm Taiwan Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ScinoPharm Taiwan has an asset utilization ratio of 23.63 percent. This indicates that the Company is making NT$0.24 for each dollar of assets. An increasing asset utilization means that ScinoPharm Taiwan is more efficient with each dollar of assets it utilizes for everyday operations.ScinoPharm Taiwan Ownership Allocation
ScinoPharm Taiwan shows a total of 790.74 Million outstanding shares. ScinoPharm Taiwan maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.ScinoPharm Taiwan Profitability Analysis
The company reported the revenue of 2.76 B. Net Income was 243.47 M with profit before overhead, payroll, taxes, and interest of 1.28 B.About ScinoPharm Taiwan Valuation
Our relative valuation model uses a comparative analysis of ScinoPharm Taiwan. We calculate exposure to ScinoPharm Taiwan's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ScinoPharm Taiwan's related companies.ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan. SCINOPHARM TAIWAN operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.
8 Steps to conduct ScinoPharm Taiwan's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates ScinoPharm Taiwan's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct ScinoPharm Taiwan's valuation analysis, follow these 8 steps:- Gather financial information: Obtain ScinoPharm Taiwan's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine ScinoPharm Taiwan's revenue streams: Identify ScinoPharm Taiwan's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research ScinoPharm Taiwan's industry and market trends, including the size of the market, growth rate, and competition.
- Establish ScinoPharm Taiwan's growth potential: Evaluate ScinoPharm Taiwan's management, business model, and growth potential.
- Determine ScinoPharm Taiwan's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate ScinoPharm Taiwan's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.